Zevra Therapeutics reported total net revenue of $37.8 million for the third quarter 2026, surpassing the consensus estimate of $37.08 million. The 45% year-over-year revenue growth was primarily fueled by the continued commercial scaling of MIPLYFFA in the U.S. market. The company achieved a significant earnings beat with diluted EPS of $0.26 compared to the $0.14 estimate, though bottom-line results were bolstered by $5.1 million in non-cash income from fair value adjustments related to warrant and contingent value rights liabilities.
Key Highlights
- MIPLYFFA net revenue reached $34.0 million, representing 90% of total quarterly sales and validating the rare disease franchise trajectory.
- The company received 13 new prescription enrollment forms for MIPLYFFA during the quarter, bringing the total to 197 since its U.S. launch.
- A strong liquidity position was maintained with $270.9 million in cash, equivalents, and investments, which management deems sufficient to fund current strategic priorities.
- Operational expansion led to a 22% increase in SG&A expenses to $19.1 million, driven by commercial infrastructure and launch costs.